The New York City pharma giant will gain MyoKardia’s mavacamten, an experimental heart drug that treats obstructive hypertrophic cardiomyopathy. The treatment has not been approved by the FDA yet.
“We are further strengthening our outstanding cardiovascular franchise through the addition of mavacamten, a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease,” Bristol Myers Squibb CEO Giovanni Caforio, MD, said in a news release.
Under the deal, Bristol Myers Squibb will pay MyoKardia $225 a share in cash.
More articles on pharmacy:
Bipartisan bill aims to create subscription-style model for bigger antibiotic market
Drugmakers, PBMs must jointly face insulin price-fixing lawsuit, judge rules
Drugmakers testify on pricing strategy, PBM contracting in Congress
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.